Results 191 to 200 of about 12,907 (206)

Boronic acid inhibitors of dipeptidyl peptidase IV

1995
Roger J. Snow, William W. Bachovchin
openaire   +1 more source

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Diabetes and Vascular Disease Research, 2019
Nordin M J Hanssen
exaly  

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland

Journal of the American Academy of Dermatology, 2018
Michael Benzaquen, , Philippe Berbis
exaly  

Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes

Expert Opinion on Therapeutic Patents, 2003
Koen Augustyns, Pieter Van der Veken, Kristel Senten   +2 more
exaly  

Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019
Ahmed M Kabel
exaly  

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

Current Medical Research and Opinion, 2011
Matteo Monami, Edoardo Mannucci
exaly  

Dipeptidyl peptidase‐4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase ‐4抑制剂：多靶点药物，不仅仅是降糖药)

Journal of Diabetes, 2014
Zhiguang Zhou
exaly  

Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

Expert Opinion on Investigational Drugs, 2005
Rolf Mentlein
exaly  

Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors

Bioorganic and Medicinal Chemistry Letters, 2006
Carl S Crysler, Bruce E Tomczuk
exaly  

The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study

Diabetes Research and Clinical Practice, 2018
John-Michael Gamble, Laurie K Twells, William K Midodzi   +2 more
exaly